查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1968592

Keytruda市場分析及至2035年預測：按類型、產品類型、應用、最終用戶、技術、製程、部署類型、功能、階段及解決方案分類

Keytruda Market Analysis and Forecast to 2035: Type, Product, Application, End User, Technology, Process, Deployment, Functionality, Stage, Solutions
出版日期: | 出版商: Global Insight Services | 英文 417 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

Keytruda市場預計將從2024年的282億美元成長到2034年的702億美元，複合年成長率約為9.5%。 Keytruda市場涵蓋帕博利珠單抗（Pembrolizumab）的分銷和開發，帕博利珠單抗是一種免疫療法藥物，透過抑制PD-1路徑標靶治療多種癌症。推動市場成長的因素包括腫瘤適應症的擴大、聯合治療的日益普及以及全球癌症患者群體的不斷成長。 Keytruda在提高存活率方面的有效性正在推動市場需求，而持續的研發投入和監管核准將進一步提升市場的潛力。

Keytruda市場正經歷強勁成長，這主要得益於其在多種癌症類型中的卓越療效。腫瘤領域尤為突出，Keytruda在非小細胞肺癌和黑色素瘤等癌症的治療中展現出優異的療效。這些細分領域至關重要，因為它們的發生率高，且患者對Keytruda的反應顯著。此外，尿路上皮癌和頭頸癌領域也因其不斷擴展的臨床應用和良好的治療效果而備受關注。免疫療法領域也呈現顯著成長，Keytruda作為查核點抑制劑的功效提升了其市場吸引力。持續的研發投入不斷拓展Keytruda的適應症並改善病患療效，進一步推動了這項成長。此外，Keytruda與其他藥物合併使用的聯合治療正成為極具前景的策略，能夠產生協同效應並擴大市場潛力。個人化醫療的持續發展進一步鞏固了Keytruda的市場地位，使其成為癌症治療模式中的基石藥物。

市場區隔
類型 單株抗體、查核點抑制劑、免疫療法
產品形式 管瓶、預填充式注射器、冷凍乾燥產品、液體
適應症 腫瘤學、非小細胞肺癌、惡性黑色素瘤、頭頸癌、腎細胞癌、何傑金氏淋巴瘤、尿路上皮癌、胃癌、子宮頸癌
最終用戶 醫院、診所、癌症治療中心和研究機構
科技 生物技術、重組DNA技術、單株抗體生產
過程 生產製造、分銷、品管和法規遵從
部署 住院、門診病人和居家照護
功能 治療性、預防性、安寧療護性
步 臨床試驗、上市後監測及商業化
解決方案 患者援助計劃、數位健康解決方案

市場概況：

憑藉其卓越的療效和不斷擴大的適應症，Keytruda 已佔據免疫療法市場的重要佔有率。我們與價值提案相符的定價策略，鞏固了我們的競爭優勢。近期推出的新產品，憑藉著創新配方和擴展的治療適應症，進一步增強了我們的市場地位。這些策略舉措鞏固了 Keytruda 在不斷變化的市場動態中的市場地位。儘管競爭基準分析清楚展現了 Keytruda 的優越性，但Opdivo和TECENTRIQ等競爭對手也構成了嚴峻的挑戰。監管環境，尤其是在美國和歐洲，正影響市場趨勢，其嚴格的核准流程和報銷政策令人擔憂。市場的特點是積極的研發投入，這促進了創新並推動了市場發展。 Keytruda 的未來成長得益於正在進行的臨床試驗和策略合作，確保了我們在競爭激烈的市場環境中保持韌性。

主要趨勢和促進因素：

受癌症免疫療法進展和癌症發病率上升的推動，Keytruda市場正經歷強勁成長。一個關鍵趨勢是Keytruda在聯合治療中的應用日益廣泛，從而提高了治療效果並擴大了臨床應用範圍。持續的研究和臨床試驗正在探索Keytruda與其他免疫腫瘤藥物和標靶治療的新型聯合療法，進一步支持了這一趨勢。另一個關鍵促進因素是Keytruda核准用於治療多種癌症，包括黑色素瘤、肺癌和膀胱癌。這些核准正在推動市場擴張，並擴大患者獲得這種創新療法的機會。此外，對個人化醫療的日益重視正在加速開發以生物標記主導的方法，以最佳化Keytruda的治療潛力。製藥公司之間的策略聯盟和夥伴關係也對市場產生影響，這些聯盟和合作旨在加強其藥物開發平臺和商業性覆蓋範圍。在尚未開發的市場，尤其是在醫療基礎設施不斷改進、人們對先進癌症療法的認知不斷提高的發展中地區，新的機會正在湧現。這些趨勢使Keytruda市場處於持續成長和創新的有利地位。

限制與挑戰：

Keytruda市場目前面臨許多重大限制與挑戰。首要障礙是治療費用高昂，不僅限制了許多病患的用藥，也加重了醫療預算的負擔。此外，免疫療法藥物複雜的法規環境也減緩了市場准入和擴張速度，阻礙了市場成長。另一個挑戰是競爭療法的出現，這可能會侵蝕Keytruda的市佔率並影響其盈利。此外，個人化治療方法的需求也增加了治療標準化的難度，加重了醫療服務提供者的負擔。最後，患者對免疫療法的反應存在個別差異，因此需要持續進行研發，這在時間和成本方面都可能造成沉重的負擔。總而言之，這些因素構成了Keytruda市場必須克服的障礙，才能維持其成長動能。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 單株抗體
    • 查核點抑制劑
    • 免疫治療藥物
  • 市場規模及預測：依產品分類
    • 管瓶
    • 預填充式注射器
    • 冷凍乾燥
    • 液體溶液
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 非小細胞肺癌
    • 黑色素瘤
    • 頭頸癌
    • 腎臟細胞癌
    • 何傑金氏淋巴瘤
    • 尿路上皮癌
    • 胃癌
    • 子宮頸癌
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 醫療
    • 癌症治療中心
    • 研究所
  • 市場規模及預測：依技術分類
    • 生物技術
    • 重組DNA技術
    • 單株抗體生產
  • 市場規模及預測：依製程分類
    • 製造業
    • 分配
    • 品管
    • 監理合規
  • 市場規模及預測：依發展狀況
    • 住院病人
    • 門診治療
    • 居家醫療
  • 市場規模及預測：依功能分類
    • 按治療區域
    • 預防性藥物
    • 安寧療護
  • 市場規模及預測：依階段分類
    • 臨床試驗
    • 上市後監測
    • 商業化
  • 市場規模及預測：按解決方案分類
    • 患者援助計劃
    • 數位健康解決方案

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Seagen
  • BeiGene
  • MacroGenics
  • Innovent Biologics
  • Zymeworks
  • Arcus Biosciences
  • CStone Pharmaceuticals
  • I-Mab Biopharma
  • Junshi Biosciences
  • Harbour BioMed
  • Hutchmed
  • Kura Oncology
  • Compugen
  • Immunocore
  • OncoSec Medical
  • Agenus
  • F-star Therapeutics
  • Pieris Pharmaceuticals
  • Apexigen
  • Oncologie

第9章：關於我們

簡介目錄
Product Code: GIS33155

Keytruda Market is anticipated to expand from $28.2 billion in 2024 to $70.2 billion by 2034, growing at a CAGR of approximately 9.5%. The Keytruda Market encompasses the distribution and development of pembrolizumab, an immunotherapy drug targeting various cancers by inhibiting the PD-1 pathway. This market is driven by its expanding indications across oncology, growing adoption in combination therapies, and increasing prevalence of cancer globally. Keytruda's efficacy in improving survival rates fuels demand, while ongoing research and regulatory approvals further enhance its market potential.

The Keytruda market is experiencing robust growth, propelled by its efficacy in treating various cancer types. The oncology segment is at the forefront, with non-small cell lung cancer and melanoma treatments demonstrating superior performance. These sub-segments are crucial due to their high prevalence and the significant patient response to Keytruda. Following closely, the urothelial carcinoma and head and neck cancer sub-segments are gaining traction, driven by expanding clinical applications and positive therapeutic outcomes. The immunotherapy segment is also witnessing substantial growth, with Keytruda's role as a checkpoint inhibitor enhancing its appeal. This growth is underscored by ongoing research and development efforts, which are broadening its indications and improving patient outcomes. Additionally, the combination therapy approach, integrating Keytruda with other agents, is emerging as a promising strategy, offering synergistic benefits and extending its market potential. The continuous evolution of personalized medicine further augments Keytruda's market trajectory, positioning it as a cornerstone in cancer treatment paradigms.

Market Segmentation
TypeMonoclonal Antibodies, Checkpoint Inhibitors, Immunotherapy Agents
ProductVials, Pre-filled Syringes, Lyophilized, Liquid Solutions
ApplicationOncology, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Renal Cell Carcinoma, Hodgkin Lymphoma, Urothelial Carcinoma, Gastric Cancer, Cervical Cancer
End UserHospitals, Clinics, Cancer Treatment Centers, Research Institutes
TechnologyBiotechnology, Recombinant DNA Technology, Monoclonal Antibody Production
ProcessManufacturing, Distribution, Quality Control, Regulatory Compliance
DeploymentInpatient, Outpatient, Homecare
FunctionalityTherapeutic, Prophylactic, Palliative
StageClinical Trials, Post-Market Surveillance, Commercialization
SolutionsPatient Support Programs, Digital Health Solutions

Market Snapshot:

Keytruda commands a significant share in the immunotherapy market, driven by its efficacy and expanding indications. Its pricing strategy aligns with its value proposition, maintaining competitive positioning. Recent product launches have reinforced its market presence, leveraging innovative formulations and expanded therapeutic applications. These strategic initiatives have bolstered Keytruda's standing amidst evolving market dynamics. Competitive benchmarking reveals Keytruda's dominance, yet rivals like Opdivo and Tecentriq present formidable challenges. Regulatory landscapes, particularly in the U.S. and Europe, influence market trajectories with stringent approval processes and reimbursement policies. The market is characterized by robust R&D investment, fostering innovation and driving market evolution. Keytruda's future growth is supported by ongoing clinical trials and strategic partnerships, ensuring its resilience in a competitive landscape.

Geographical Overview:

The Keytruda market is witnessing substantial growth across diverse regions, each presenting unique opportunities. North America remains a dominant player due to its advanced healthcare infrastructure and extensive research initiatives. The region's focus on innovative cancer therapies bolsters Keytruda's market presence. Europe follows, with robust healthcare systems and increased government support for immunotherapy treatments driving demand. In Asia Pacific, rapid urbanization and rising cancer incidences are propelling market expansion. Countries like China and India are emerging as significant growth pockets, with increasing healthcare investments and improved access to treatments. Latin America shows promise, with Brazil and Mexico leading the charge in adopting advanced cancer therapies. The Middle East & Africa are also gaining traction, recognizing the potential of immunotherapy in addressing unmet medical needs. The region's growing healthcare awareness and infrastructure development present lucrative opportunities for Keytruda's market penetration. These emerging markets are crucial for sustaining global Keytruda demand.

Key Trends and Drivers:

The Keytruda market is experiencing robust growth propelled by advancements in cancer immunotherapy and rising cancer prevalence. A major trend is the increasing adoption of Keytruda in combination therapies, enhancing treatment efficacy and broadening its clinical applications. This trend is supported by ongoing research and clinical trials exploring novel combinations with other immuno-oncology agents and targeted therapies. Another significant driver is the expanding approvals for Keytruda across various cancer types, including melanoma, lung, and bladder cancer. These approvals are fueling market expansion and increasing patient access to innovative treatments. Additionally, the growing focus on personalized medicine is accelerating the development of biomarker-driven approaches, optimizing Keytruda's therapeutic potential. The market is further influenced by strategic collaborations and partnerships among pharmaceutical companies, aiming to enhance drug development pipelines and commercial reach. Opportunities are emerging in untapped markets, particularly in developing regions, where healthcare infrastructure is improving, and awareness of advanced cancer therapies is rising. These dynamics position the Keytruda market for sustained growth and innovation.

Restraints and Challenges:

The Keytruda market is currently encountering several significant restraints and challenges. A primary obstacle is the high cost of treatment, which limits accessibility for many patients and strains healthcare budgets. Additionally, the complex regulatory environment surrounding immunotherapy drugs can delay market entry and expansion, creating barriers for growth. Another challenge is the emergence of competitive therapies, which could potentially erode Keytruda's market share and impact profitability. Furthermore, the need for personalized treatment regimens complicates the standardization of care, increasing the burden on healthcare providers. Lastly, the variability in patient response to immunotherapy necessitates ongoing research and development, which can be both time-consuming and costly. These factors collectively present hurdles that the Keytruda market must navigate to sustain its trajectory.

Key Players:

Seagen, BeiGene, MacroGenics, Innovent Biologics, Zymeworks, Arcus Biosciences, CStone Pharmaceuticals, I-Mab Biopharma, Junshi Biosciences, Harbour BioMed, Hutchmed, Kura Oncology, Compugen, Immunocore, OncoSec Medical, Agenus, F-star Therapeutics, Pieris Pharmaceuticals, Apexigen, Oncologie

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by End User
  • 2.5 Key Market Highlights by Technology
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Deployment
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Stage
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Checkpoint Inhibitors
    • 4.1.3 Immunotherapy Agents
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Vials
    • 4.2.2 Pre-filled Syringes
    • 4.2.3 Lyophilized
    • 4.2.4 Liquid Solutions
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Oncology
    • 4.3.2 Non-Small Cell Lung Cancer
    • 4.3.3 Melanoma
    • 4.3.4 Head and Neck Cancer
    • 4.3.5 Renal Cell Carcinoma
    • 4.3.6 Hodgkin Lymphoma
    • 4.3.7 Urothelial Carcinoma
    • 4.3.8 Gastric Cancer
    • 4.3.9 Cervical Cancer
  • 4.4 Market Size & Forecast by End User (2020-2035)
    • 4.4.1 Hospitals
    • 4.4.2 Clinics
    • 4.4.3 Cancer Treatment Centers
    • 4.4.4 Research Institutes
  • 4.5 Market Size & Forecast by Technology (2020-2035)
    • 4.5.1 Biotechnology
    • 4.5.2 Recombinant DNA Technology
    • 4.5.3 Monoclonal Antibody Production
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Manufacturing
    • 4.6.2 Distribution
    • 4.6.3 Quality Control
    • 4.6.4 Regulatory Compliance
  • 4.7 Market Size & Forecast by Deployment (2020-2035)
    • 4.7.1 Inpatient
    • 4.7.2 Outpatient
    • 4.7.3 Homecare
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Therapeutic
    • 4.8.2 Prophylactic
    • 4.8.3 Palliative
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Clinical Trials
    • 4.9.2 Post-Market Surveillance
    • 4.9.3 Commercialization
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Patient Support Programs
    • 4.10.2 Digital Health Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 End User
      • 5.2.1.5 Technology
      • 5.2.1.6 Process
      • 5.2.1.7 Deployment
      • 5.2.1.8 Functionality
      • 5.2.1.9 Stage
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 End User
      • 5.2.2.5 Technology
      • 5.2.2.6 Process
      • 5.2.2.7 Deployment
      • 5.2.2.8 Functionality
      • 5.2.2.9 Stage
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 End User
      • 5.2.3.5 Technology
      • 5.2.3.6 Process
      • 5.2.3.7 Deployment
      • 5.2.3.8 Functionality
      • 5.2.3.9 Stage
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 End User
      • 5.3.1.5 Technology
      • 5.3.1.6 Process
      • 5.3.1.7 Deployment
      • 5.3.1.8 Functionality
      • 5.3.1.9 Stage
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 End User
      • 5.3.2.5 Technology
      • 5.3.2.6 Process
      • 5.3.2.7 Deployment
      • 5.3.2.8 Functionality
      • 5.3.2.9 Stage
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 End User
      • 5.3.3.5 Technology
      • 5.3.3.6 Process
      • 5.3.3.7 Deployment
      • 5.3.3.8 Functionality
      • 5.3.3.9 Stage
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 End User
      • 5.4.1.5 Technology
      • 5.4.1.6 Process
      • 5.4.1.7 Deployment
      • 5.4.1.8 Functionality
      • 5.4.1.9 Stage
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 End User
      • 5.4.2.5 Technology
      • 5.4.2.6 Process
      • 5.4.2.7 Deployment
      • 5.4.2.8 Functionality
      • 5.4.2.9 Stage
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 End User
      • 5.4.3.5 Technology
      • 5.4.3.6 Process
      • 5.4.3.7 Deployment
      • 5.4.3.8 Functionality
      • 5.4.3.9 Stage
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 End User
      • 5.4.4.5 Technology
      • 5.4.4.6 Process
      • 5.4.4.7 Deployment
      • 5.4.4.8 Functionality
      • 5.4.4.9 Stage
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 End User
      • 5.4.5.5 Technology
      • 5.4.5.6 Process
      • 5.4.5.7 Deployment
      • 5.4.5.8 Functionality
      • 5.4.5.9 Stage
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 End User
      • 5.4.6.5 Technology
      • 5.4.6.6 Process
      • 5.4.6.7 Deployment
      • 5.4.6.8 Functionality
      • 5.4.6.9 Stage
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 End User
      • 5.4.7.5 Technology
      • 5.4.7.6 Process
      • 5.4.7.7 Deployment
      • 5.4.7.8 Functionality
      • 5.4.7.9 Stage
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 End User
      • 5.5.1.5 Technology
      • 5.5.1.6 Process
      • 5.5.1.7 Deployment
      • 5.5.1.8 Functionality
      • 5.5.1.9 Stage
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 End User
      • 5.5.2.5 Technology
      • 5.5.2.6 Process
      • 5.5.2.7 Deployment
      • 5.5.2.8 Functionality
      • 5.5.2.9 Stage
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 End User
      • 5.5.3.5 Technology
      • 5.5.3.6 Process
      • 5.5.3.7 Deployment
      • 5.5.3.8 Functionality
      • 5.5.3.9 Stage
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 End User
      • 5.5.4.5 Technology
      • 5.5.4.6 Process
      • 5.5.4.7 Deployment
      • 5.5.4.8 Functionality
      • 5.5.4.9 Stage
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 End User
      • 5.5.5.5 Technology
      • 5.5.5.6 Process
      • 5.5.5.7 Deployment
      • 5.5.5.8 Functionality
      • 5.5.5.9 Stage
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 End User
      • 5.5.6.5 Technology
      • 5.5.6.6 Process
      • 5.5.6.7 Deployment
      • 5.5.6.8 Functionality
      • 5.5.6.9 Stage
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 End User
      • 5.6.1.5 Technology
      • 5.6.1.6 Process
      • 5.6.1.7 Deployment
      • 5.6.1.8 Functionality
      • 5.6.1.9 Stage
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 End User
      • 5.6.2.5 Technology
      • 5.6.2.6 Process
      • 5.6.2.7 Deployment
      • 5.6.2.8 Functionality
      • 5.6.2.9 Stage
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 End User
      • 5.6.3.5 Technology
      • 5.6.3.6 Process
      • 5.6.3.7 Deployment
      • 5.6.3.8 Functionality
      • 5.6.3.9 Stage
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 End User
      • 5.6.4.5 Technology
      • 5.6.4.6 Process
      • 5.6.4.7 Deployment
      • 5.6.4.8 Functionality
      • 5.6.4.9 Stage
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 End User
      • 5.6.5.5 Technology
      • 5.6.5.6 Process
      • 5.6.5.7 Deployment
      • 5.6.5.8 Functionality
      • 5.6.5.9 Stage
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Seagen
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 BeiGene
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 MacroGenics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Innovent Biologics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Zymeworks
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Arcus Biosciences
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 CStone Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 I-Mab Biopharma
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Junshi Biosciences
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Harbour BioMed
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Hutchmed
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Kura Oncology
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Compugen
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Immunocore
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 OncoSec Medical
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Agenus
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 F-star Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Pieris Pharmaceuticals
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Apexigen
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Oncologie
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us